ClinicalTrials.gg
Status unknownNCT02448199ZDPC00213Updated May 19, 2015

Study of Association of Anti-inflammatory and Anti-rheumatic

A Phase 3 interventional study of Meloxicam and Glucosamine and Meloxicam in Osteoarthritis, sponsored by Zodiac Produtos Farmaceuticos S.A.. Status unknown. Open to participants aged 40 Years to 85 Years. Per ClinicalTrials.gov, last updated 2015-05-19.

Sponsored by Zodiac Produtos Farmaceuticos S.A. · Phase 3, Interventional, and Treatment

The sponsor has not verified this record recently (last verified May 2015), so the status shown — last known as Not yet recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
375
Allocation
Randomized
Ages
40 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 10 studies testing glucosamine in Osteoarthritis — none open to participants now, none under way, none of them phase 3. Glucosamine · Osteoarthritis.

Planned enrollment
2nd of 10
375 · median 221
Started
2015
the only one that year
Phase 3
4 of 10
none open now
Registered
8th of 10
by date
Lead sponsor
1 of 10
Zodiac Produtos Farmaceuticos S.A.

Among the 10 studies testing glucosamine in Osteoarthritis, this one is the 2nd largest by planned enrollment, is the only one that started in 2015, is one of 4 in phase 3, and was the 8th registered.

Osteoarthritis

2,975 studies on the registry are indexed under Osteoarthritis; 435 are open to participants now.

Browse Osteoarthritis studies →

Open to participants now

None of the 10 studies testing glucosamine in Osteoarthritis is open now. The open studies under Osteoarthritis, anywhere →

About glucosamine

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 285 Osteoarthritis studies recruiting now, 157 (55%) set no upper age limit and 71 (25%) stop at 75 or younger; 22 take children under 18; 30 take healthy volunteers.

This study: 40 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 10 studies testing glucosamine in Osteoarthritis as a file.
02

Study summary

Phase III Study, double-blind, comparing association of anti-inflammatory and anti-rheumatic in 375 subjects with knee osteoarthritis.

Read the detailed description

Evaluation after 12 weeks of treatment, in 3 arms, the efficacy and safety of the association.

03

Conditions studied

  • Osteoarthritis

Keywords

  • pain
  • Knee
04

Who can participate

Ages eligible
40 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signs the Form
  • Age between 40 and 85 years
  • osteoarthritis of the knee according to clinical and radiological criteria of the American College of Rheumatology

Exclusion criteria

Exclusion Criteria:

  • Cardiovascular disease
  • Serious chronic comorbidity
  • to any component of the study drugs
  • > 30 kg / m²
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
375 participants (estimated)

Study arms

  • Experimental
    Kit 1 ( ML + CG ) + P

    One sachet meloxicam and glucosamine and 1 placebo tablet once a day for 12 weeks One sachet

    Drug: Meloxicam and Glucosamine

  • Active comparator
    Kit 2 ( ML + P)

    One tablet of meloxicam and one sachet of placebo once per day for 12 weeks

    Drug: Meloxicam

  • Active comparator
    Kit 3 ( P+ GC)

    One sachet of glucosamine and one tablet placebo once a day for 12 weeks

    Drug: Glucosamine

Interventions

  • DrugMeloxicam and Glucosamine

    Drug pages: Meloxicam · Glucosamine

    Experimental

    Also known as: Association Anti-inflamatory/Anti-rheumatic

  • Active Comparator

    Also known as: Anti-inflamatory/Placebo

  • Active Comparator

    Also known as: Anti-rheumatic/Placebo

06

What researchers measure

Primary outcomes

  1. Efficacy measured by decrease in score algofunctional Lequesne index after 12 weeks from the start of treatment

    Decrease in score of algofunctional Lequesne index after 12 weeks from the start of treatment

    Time frame: 12 weeks

Secondary outcomes

  1. Safety measured by frequency of adverse event

    Safety as measured by total frequency of adverse event during the 12 weeks of treatment

    Time frame: 12 weeks

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2015, a primary completion of Jun 2016 and a completion of Jul 2016. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
May 11, 2015
First posted
May 19, 2015
Start
Jul 2015
Primary completionEst.
Jun 2016
CompletionEst.
Jul 2016
Last update
May 19, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 19, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02448199
Lead sponsor
Zodiac Produtos Farmaceuticos S.A.
Collaborators
Eurotrials Brasil Consultores Cientificos Ltda
Responsible party
Sponsor
First posted
May 19, 2015
Start date
Jul 2015
Primary completion
Jun 2016 (estimated)
Completion
Jul 2016 (estimated)
Last update
May 19, 2015

Study contacts

Carine F Sanches, Pharmacist
Contact
carine.sanches@zodiac.com.br
55 11 55015332
Valery F Carvalho, Biologist
Contact
Edio Costa, Doctor
study chair · CRM

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in May 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Meloxicam · Glucosamine

Start the discussion